FindTrial
Sign In

Treatment of Metastatic Cancer in Terminally Diagnosed Patients

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT05491928
Enrollment
Unknown
Registered
2022-08-08
Start date
Unknown
Completion date
Unknown
Last updated
2022-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Cancer

Brief summary

The objective is to provide terminally diagnosed patients with a last line of treatment while improving overall quality of life. Tempol can be added to any chemotherapy regimen to potentially reduce side effects and overcome chemoresistance.

Detailed description

The objective is to provide terminally diagnosed patients assigned to palliative care and palliative chemotherapy a last line treatment with Tempol. In vivo studies have shown Tempol to work synergistically with a number of chemotherapy agents increasing treatment response and reducing chemoresistance. Additionally, Tempol has been shown to provide protection to non-cancerous cells allowing for increased chemotherapy dosing by reducing side effects. Tempol inhibits HIF-1/VEGF among others in cancerous cells while upregulating GSH/NrF2 among others in non-cancerous cells.

Interventions

DRUGTempol

Tempol will be given as an adjunct to chemotherapy.

Sponsors

Matrix Biomed, Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL

Inclusion criteria

* metastatic terminally diagnosed cancer

Exclusion criteria

\-

Countries

United States

Contacts

Primary ContactBenji Crane
bjcrane@matrixbiomed.com6264376506

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026